Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2

Conditions

Myasthenia Gravis 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Hodgkin Disease 1

Interventions

Cyclophosphamide 910Carboplatin 788pembrolizumab 747Paclitaxel 744Bevacizumab 716Cisplatin 709Gemcitabine 621Docetaxel 584Rituximab 558Radiotherapy 548Dexamethasone 511Nivolumab 491Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 358Pemetrexed 339Cytarabine 335Oxaliplatin 335Lenalidomide 328Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 316Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 277

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × rhoA GTP-Binding Protein × Clear all
NCT05218096 2025-01-09

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Phase 2 Terminated
70 enrolled 14 charts

Myasthenia Gravis

NCT02867618 2021-07-16

Carfilzomib and TGR-1202 in Treatment of R/R Lymphoma

Columbia University

Phase 1/2 Terminated
14 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin

NCT03178201 2021-07-16

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Columbia University

Phase 2 Terminated
5 enrolled 5 charts
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡